Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine.
Latest Ratings for PRAX
Date | Firm | Action | From | To |
---|
Dec 2021 | HC Wainwright & Co. | Initiates Coverage On | | Buy |
Aug 2021 | B of A Securities | Initiates Coverage On | | Buy |
Apr 2021 | William Blair | Initiates Coverage On | | Outperform |
View More Analyst Ratings for PRAX
View the Latest Analyst Ratings
read more